Text Size

Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)

Bacharach J., Brubaker J.W., Evans D.G., LU F., Odani-Kawabata N., Yamabe T., Wirta D.L.


  • 2024
  • American Journal of Ophthalmology
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    From the North Bay Eye Associates (J.B.), Petaluma, CA, United States; Sacramento Eye Consultants (J.W.B.), Sacramento, CA, United States; Total Eye Care, P.A.(D.G.E.), Memphis, TN, United States; Santen, Inc.(F.L., T.Y.), Emeryville, CA, United States; Santen Pharmaceutical Co., Ltd (N.O.-K., T.Y.), Osaka, Japan; Eye Research Foundation (D.L.W.), Newport Beach, CA, United States

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022